Intrinsic immune alterations in renal cell carcinoma and emerging immunotherapeutic approaches

Expert Opinion on Biological Therapy

Volumn 13, Issue 6, 2013, Pages 911-925

  Bockorny, Bruno ^a   Dasanu, Constantin A ^b  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b SAINT FRANCIS HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

Immune dysfunction; Immunomodulator; Immunotherapy; Kidney cancer; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; BMS 936559; CD4 ANTIGEN; CD59 ANTIGEN; COMPLEMENT COMPONENT C3B RECEPTOR; CXCL2 CHEMOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EVEROLIMUS; FAS LIGAND; GAMMA INTERFERON; IMA 901; INTERLEUKIN 2; INTERLEUKIN 8; IPILIMUMAB; MEGESTROL; MEMBRANE COFACTOR PROTEIN; MONOCLONAL ANTIBODY; NAVELBINE; NIVOLUMAB; PAZOPANIB; PIDILIZUMAB; PROGRAMMED DEATH 1 LIGAND ANTIBODY; RAPAMYCIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRANSCRIPTION FACTOR FOXP3; TUMOR CELL VACCINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL CYCLE REGULATION; CELL PROLIFERATION; CELLULAR IMMUNITY; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DISEASE FREE SURVIVAL; DRUG MEGADOSE; ENTEROCOLITIS; GENE OVEREXPRESSION; HORMONE DEFICIENCY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; INTERFERON INDUCTION; INTRACELLULAR SIGNALING; KIDNEY CARCINOMA; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOPENIA; LYMPHOCYTOTOXICITY; LYMPHOKINE ACTIVATED KILLER CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MEMORY T LYMPHOCYTE; METASTATIC MELANOMA; NATURAL KILLER CELL; NEPHRECTOMY; NEUTROPENIA; NEUTROPHIL; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL RATE; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR DIFFERENTIATION; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

ANGIOGENESIS INHIBITORS; CANCER VACCINES; CARCINOMA, RENAL CELL; CYTOKINES; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84877898781     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.778970     Document Type: Review

References (126)

1. Lipworth L TR, McLaughlin JK. The epidemiology of renal cell carcinoma. J Urol 2006;176:2353-8
2. Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Rev Urol 2010;7:245-57
3. Mathew A, Devesa SS, Fraumeni JF Jr, et al. Global increases in kidney cancer incidence, 1973-1992. Eur J Cancer Prev 2002;11:171-8
4. Ng CS, Novick AC, Tannenbaum CS, et al. Mechanisms of immune evasion by renal cell carcinoma: Tumor-induced Tlymphocyte apoptosis and NFkappaB suppression. Urology 2002;59:9-14
5. Wysocki PJ, Zolnierek J, Szczylik C, et al. Recent developments in renal cell cancer immunotherapy. Expert Opin Biol Ther 2007;7:727-37
6. Egeter O, Mocikat R, Ghoreschi K, et al. Eradication of disseminated lymphomas with CpG-DNA activated T helper type 1 cells from nontransgenic mice. Cancer Res 2000;60:1515-20
7. Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005;54:721-8
8. Ostrand-Rosenberg S. CD4+ T lymphocytes: A critical component of antitumor immunity. Cancer Invest 2005;23:413-19
9. Wang Q, Redovan C, Tubbs R, et al. Selective cytokine gene expression in renal cell carcinoma tumor cells and tumor-infiltrating lymphocytes. Int J Cancer 1995;61:780-5
10. Romero JM, Aptsiauri N, Vazquez F, et al. Analysis of the expression of HLA class I, proinflammatory cytokines and chemokines in primary tumors from patients with localized and metastatic renal cell carcinoma. Tissue Antigens 2006;68:303-10
11. Frankenberger B, Noessner E, Schendel DJ. Immune suppression in renal cell carcinoma. Semin Cancer Biol 2007;17:330-43
12. Storkel S, Keymer R, Steinbach F, et al. Reaction patterns of tumor infiltrating lymphocytes in different renal cell carcinomas and oncocytomas. Prog Clin Biol Res 1992;378:217-23
13. Strand S, Hofmann WJ, Hug H, et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells-A mechanism of immune evasion? Nat Med 1996;2:1361-6
14. Zeytun A, Hassuneh M, Nagarkatti M, et al. Fas-Fas ligand-based interactions between tumor cells and tumor-specific cytotoxic T lymphocytes: A lethal two-way street. Blood 1997;90:1952-9
15. Uzzo RG, Rayman P, Kolenko V, et al. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. Clin Cancer Res 1999;5:1219-29
16. Maeurer MJ, Martin DM, Castelli C, et al. Host immune response in renal cell cancer: Interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes. Cancer Immunol Immunother 1995;41:111-21
17. Onishi T, Ohishi Y, Imagawa K, et al. An assessment of the immunological environment based on intratumoral cytokine production in renal cell carcinoma. BJU Int 1999;83:488-92
18. Onishi T, Ohishi Y, Goto H, et al. An assessment of the immunological status of patients with renal cell carcinoma based on the relative abundance of T-helper 1- and -2 cytokine-producing CD4+ cells in peripheral blood. BJU Int 2001;87:755-9
19. Bromwich EJ, McArdle PA, Canna K, et al. The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer. Br J Cancer 2003;89:1906-8
20. Hotta K, Sho M, Fujimoto K, et al. Prognostic significance of CD45RO+ memory T cells in renal cell carcinoma. Br J Cancer 2011;105:1191-6
21. Murakami Y, Kanda K, Yokota K, et al. Prognostic significance of immuno-proteosome subunit expression in patients with renal-cell carcinoma: A preliminary study. Mol Urol 2001;5:113-19
22. Seliger B, Maeurer MJ, Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol Today 2000;21:455-64
23. Cavalcanti E, Gigante M, Mancini V, et al. JAK3/STAT5/6 pathway alterations are associated with immune deviation in CD8 T cells in renal cell carcinoma patients. J Biomed Biotechnol 2010;2010:935764
24. Nakano O, Sato M, Naito Y, et al. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: Clinicopathologic demonstration of antitumor immunity. Cancer Res 2001;61:5132-6
25. Igarashi T, Takahashi H, Tobe T, et al. Effect of tumor-infiltrating lymphocyte subsets on prognosis and susceptibility to interferon therapy in patients with renal cell carcinoma. Urol Int 2002;69:51-6
26. Asseman C, von Herrath M. About CD4pos CD25pos regulatory cells. Autoimmun Rev 2002;1:190-7
27. Tanaka H, Tanaka J, Kjaergaard J, et al. Depletion of CD4+CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J Immunother 2002;25:207-17
28. Golgher D, Jones E, Powrie F, et al. Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur J Immunol 2002;32:3267-75
29. Griffiths RW, Elkord E, Gilham DE, et al. Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother 2007;56:1743-53
30. Liotta F, Gacci M, Frosali F, et al. Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma. BJU Int 2011;107:1500-6
31. Sakaguchi S, Sakaguchi N, Shimizu J, et al. Immunologic tolerance maintained by CD25p CD4p regulatory T cells: Their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001;182:18-32
32. Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007;117:1167-74
33. Ko JS, Zea AH, Rini BI, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009;15:2148-57
34. Desar IM, Jacobs JFM, Hulsbergen-vandeKaa CA, et al. Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients. Int J Cancer 2011;129:507-12
35. Cesana GC, DeRaffele G, Cohen S, et al. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 2006;24:1169-77
36. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005;115:3623-33
37. Finn OJ. Immuno-oncology: Understanding the function and dysfunction of the immune system in cancer. Ann Oncol 2012;23(Suppl 8):viii6-9
38. Gabrilovich D, Pisarev V. Tumor escape from immune response: Mechanisms and targets of activity. Curr Drug Targets 2003;4:525-236
39. Kagi D, Vignaux F, Ledermann B, et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994;265:528-30
40. Lowin B, Hahne M, Mattmann C, et al. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 1994;370:650-2
41. Kayagaki N, Yamaguchi N, Nakayama M, et al. Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity. J Immunol 1999;162:2639-47
42. Kayagaki N, Yamaguchi N, Nakayama M, et al. Expression and function of TNF-related apoptosisinducing ligand on murine activated NK cells. J Immunol 1999;163:1906-13
43. Liu CC, Walsh CM, Young JD. Perforin: Structure and function. Immunol Today 1995;16:194-201
44. Lowin B, Peitsch MC, Tschopp J. Perforin and granzymes: Crucial effector molecules in cytolytic T lymphocyte and natural killer cell-mediated cytotoxicity. Curr Top Microbiol Immunol 1995;198:1-24
45. Smyth MJ, Trapani JA. Granzymes: Exogenous proteinases that induce target cell apoptosis. Immunol Today 1995;16:202-6
46. Stanley AJ, Gough MJ, Banks RE, et al. Renal carcinoma cell lines inhibit natural killer activity via the CD94 receptor molecule. Cancer Immunol Immunother 2001;50:260-8
47. Hofmann R, Lehmer A, Reidel G, et al. Natural killer cells in patients with renal cell cancer. Urol Int 1985;40(5):251-6
48. Dadian G, Riches PG, Henderson DC, et al. Immunological parameters in peripheral blood of patients with renal cell carcinoma before and after nephrectomy. Br J Urol 1994;74(1):15-22
49. Buzio C, Andrulli S, Santi R, et al. Long-term immunotherapy with low-dose interleukin-2 and interferon-alpha in the treatment of patients with advanced renal cell carcinoma. Cancer 2001;92:2286-2
50. Pavone L, Andrulli S, Santi R, et al. Long-term treatment with low doses of interleukin-2 and interferon-alpha: Immunological effects in advanced renal cell cancer. Cancer Immunol Immunother 2001;50:82-6
51. Pavone L, Fanti G, Bongiovanni C, et al. Natural killer cell cytotoxicity is enhanced by very low doses of rIL-2 and rIFN-alpha in patients with renal cell carcinoma. Med Oncol 2009;26:38-44
52. Porta C, Bonomi L, Lillaz B, et al. Renal cell carcinoma-induced immunosuppression: An immunophenotypic study of lymphocyte subpopulations and circulating dendritic cells. Anticancer Res 2007;27:165-73
53. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005;5:296-306
54. Melief CJ. Cancer immunotherapy by dendritic cells. Immunity 2008;29:372-83
55. Middel P, Brauneck S, Meyer W, et al. Chemokine-mediated distribution of dendritic cell subsets in renal cell carcinoma. BMC Cancer 2010;10:578
56. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52
57. Caux C, Ait-Yahia S, Chemin K, et al. Dendritic cell biology and regulation of dendritic cell trafficking by chemokines. Springer Semin Immunopathol 2000;22:345-69
58. Schwaab T, Schned AR, Heaney JA, et al. In vivo description of dendritic cells in human renal cell carcinoma. J Urol 1999;162:567-73
59. Gigante M, Blasi A, Loverre A, et al. Dysfunctional DC subsets in RCC patients: Ex vivo correction to yield an effective anti-cancer vaccine. Mol Immunol 2009;46(5):893-901
60. Oyama T, Ran S, Ishida T, et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol 1998;160:1224-32
61. Lusini L, Tripodi SA, Rossi R, et al. Altered glutathione anti-oxidant metabolism during tumor progression in human renal-cell carcinoma. Int J Cancer 2001;91:55-9
62. Kudo D, Rayman P, Horton C, et al. Gangliosides expressed by the renal cell carcinoma cell line SK-RC-45 are involved in tumor-induced apoptosis of T cells. Cancer Res 2003;63:1676-83
63. Kobayashi M, Suzuki K, Yashi M, et al. Tumor infiltrating dendritic cells predict treatment response to immmunotherapy in patients with metastatic renal cell carcinoma. Anticancer Res 2007;27:1137-41
64. Fridlender ZV, Albelda SM. Tumor-associated neutrophils: Friend or foe? Carcinogenesis 2012;33:949-55
65. Jensen HK, Donskov F, Marcussen N, et al. Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J Clin Oncol 2009;27:4709-17
66. Fridlender ZG, Sun J, Kim S, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: ''N1'' versus ''N2'' TAN. Cancer Cell 2009;16:183-94
67. Lopez-Lago MA, Posner S, Thodima VJ, et al. Neutrophil chemokines secreted by tumor cells mount a lung antimetastatic response during renal cell carcinoma progression. Oncogene 2012; Epub ahead of print
68. Daurkin I, Eruslanov E, Stoffs T, et al. Tumor-associated macrophages mediate immunosuppression in the renal cancer microenvironment by activating the 15-lipoxygenase-2 pathway. Cancer Res 2011;71:6400-9
69. Sunderkotter C, Steinbrink K, Goebeler M, et al. Macrophages and angiogenesis. J Leukoc Biol 1994;55:410-22
70. Toge H, Inagaki T, Kojimoto Y, et al. Angiogenesis in renal cell carcinoma: The role of tumor-associated macrophages. Int J Urol 2009;16:801-7
71. Cursiefen C, Chen L, Borges LP, et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 2004;113:1040-50
72. Hamada I, Kato M, Yamasaki T, et al. Clinical effects of tumor-associated macrophages and dendritic cells on renal cell carcinoma. Anticancer Res 2002;22:4281-4
73. Komohara Y, Hasita H, Ohnishi K, et al. Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma. Cancer Sci 2011;102(7):1424-31
74. Rayman P, Uzzo RG, Kolenko V, et al. Tumor-induced dysfunction in interleukin-2 production and interleukin-2 receptor signaling: A mechanism of immune escape. Cancer J Sci Am 2000;6(Suppl 1):S81-7
75. Kolenko V, Wang Q, Riedy MC, et al. Tumor-induced suppression of T lymphocyte proliferation coincides with inhibition of Jak3 expression and IL-2 receptor signaling: Role of soluble products from human renal cell carcinomas. J Immunol 1997;159:3057-67
76. Konig B, Steinbach F, Janocha B, et al. The differential expression of proinflammatory cytokines IL-6, IL-8 and TNF-alpha in renal cell carcinoma. Anticancer Res 1999;19:1519-24
77. Huang D, Ding Y, Zhou M, et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 2010;70:1063-71
78. Porta C, Paglino C, Imarisio I, et al. Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients. Oncology 2013;84:115-22
79. Fitzgerald JP, Nayak B, Shanmugasundaram K, et al. Nox4 mediates renal cell carcinoma cell invasion through hypoxia-induced interleukin 6- and 8- production. PLoS One 2012;7(1):e30712
80. Chuang MJ, Sun KH, Tang SJ, et al. Tumor-derived tumor necrosis factor-alpha promotes progression and epithelial-mesenchymal transition in renal cell carcinoma cells. Cancer Sci 2008;99:905-13
81. Mukhopadhyay D, Knebelmann B, Cohen HT, et al. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol Cell Biol 1997;17:5629-39
82. Xu L, Tong R, Cochran DM, et al. Blocking platelet derived growth factor- D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model. Cancer Res 2005;65:5711-19
83. Hillman GG, Puri RK, Kukuruga MA, et al. Growth and major histocompatibility antigen expression regulation by IL-4, interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha) on human renal cell carcinoma. Clin Exp Immunol 1994;96:476-83
84. Tran HT, Liu Y, Zurita AJ, et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: A retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol 2012;13:827-37
85. Zurita AJ, Jonasch E, Wang X, et al. A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann Oncol 2012;23:46-52
86. Fishelson Z, Donin N, Zell S, et al. Obstacles to cancer immunotherapy: Expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 2003;40:109-23
87. Blok VT, Daha MR, Tijsma OM, et al. A possible role of CD46 for the protection in vivo of human renal tumor cells from complement-mediated damage. Lab Invest 2000;80:335-44
88. Liszewski MK, Farries TC, Lublin DM, et al. Control of the complement system. Adv Immunol 1996;61:201-83
89. Nicholson-Weller A, Burge J, Fearon DT, et al. Isolation of a human erythrocyte membrane glycoprotein with decay- accelerating activity for C3 convertases of the complement system. J Immunol 1982;129:184-9
90. Niehans GA, Cherwitz DL, Staley NA, et al. Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am J Pathol 1996;149:129-42
91. Terachi T, Stanescu G, Pontes JE, et al. Coexistence of autologous antibodies and decay-accelerating factor, an inhibitor of complement, on human renal tumor cells. Cancer Res 1991;51:2521-3
92. Blok VT, Gelderman KA, Tijsma OH, et al. Cytokines affect resistance of human renal tumour cells to complement-mediated injury. Scand J Immunol 2003;57:591-9
93. Alexandrescu DT, Dasanu CA. Kidney cancer therapy: New perspectives and avenues. Review. Expert Opin Pharmacother 2006;7:2481-93
94. Kappauf H, Gallmeier WM, Wunsch PH, et al. Complete spontaneous remission in a patient with metastatic non-small-cell lung cancer. Case report, review of the literature, and discussion of possible biological pathways involved. Ann Oncol 1997;8:1031-9
95. Fairlamb DJ. Spontaneous regression of metastases of renal cancer. A report of two cases including the first recorded regression following irradiation of a dominant metastasis and review of the world literature. Cancer 1981;47:2102-6
96. Kavoussi LR, Levine SR, Kadmon D, et al. Regression of metastatic renal cell carcinoma: A case report and literature review. J Urol 1986;135:1005-7
97. Drobyski WR, Quazi R. Spontaneous regression in non-Hodgkins's lymphoma: Clinical and pathogenetic considerations. Am J Hematol 1989;31:138-41
98. Bukowski RM, Novick AC. Clinical practice guidelines: Renal cell carcinoma. Cleve Clin J Med 1997;64:1-44
99. Kuebler JP, Whitehead RP, Ward DL, et al. Treatment of metastatic renal cell carcinoma with recombinant interleukin-2 in combination with vinblastine or lymphokine-activated killer cells. J Urol 1993;150:814-20
100. Coppin C, Porzsolt F, Awa A, et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005;1:CD001425
101. Hipp MM, Hilf N, Walter S, et al. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 2008;111:5610-20
102. Porta C, Paglino C, Imarisio I, et al. Immunological effects of multikinase inhibitors for kidney cancer: A clue for integration with cellular therapies? J Cancer 2011;2:333-8
103. Krusch M, Salih J, Schlicke M, et al. The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro. J Immunol 2009;183:8286-94
104. Farsaci B, Higgins JP, Hodge JW. Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy. Int J Cancer 2012;130:1948-59
105. Finke J, Ko J, Rini B, et al. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int Immunopharmacol 2011;11:856-61
106. Kujawski M, Kortylewski M, Lee H, et al. Stat3 mediates myeloid celldependent tumor angiogenesis in mice. J Clin Invest 2008;118:3367-77
107. Yang L, DeBusk LM, Fukuda K, et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004;6:409-21
108. Shojaei F, Wu X, Malik AK, et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol 2007;25:911-20
109. Crawford Y, Ferrara N. Tumor and stromal pathways mediating refractoriness/resistance to antiangiogenic therapies. Trends Pharmacol Sci 2009;30:624-30
110. Ko JS, Rayman P, Ireland J, et al. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res 2010;70:3526-36
111. Gu Y, Zhao W, Meng F, et al. Sunitinib impairs the proliferation and function of human peripheral T cell and prevents T-cell-mediated immune response in mice. Clin Immunol 2010;135:55-62
112. Dasanu CA, Clark BA III, Alexandrescu DT. mTOR-blocking agents in advanced renal cancer: An emerging therapeutic option. Expert Opin Investig Drugs 2009;18:175-87. A paper on the role of mTOR inhibitors in RCC
113. Wang Y, Wang XY, Subjeck JR, et al. Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines. Br J Cancer 2011;104:643-52
114. Alexandrescu DT, Ichim TE, Riordan NH, et al. Immunotherapy for melanoma: Current status and perspectives. J Immunother 2010;33:570-90
115. Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007;30:825-30
116. Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci 2002;99:12293-7
117. Blank C, Kuball J, Voelkl S, et al. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer 2006;119:317-27
118. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65
119. Ribas A. Tumor immunotherapy directed at PD-1. N Engl J Med 2012;366:2517-19
120. Frankenberger B, Regn S, Geiger C, et al. Cell-based vaccines for renal cell carcinoma: Genetically-engineered tumor cells and monocyte-derived dendritic cells. World J Urol 2005;23:166-74
121. Galligioni E, Quaia M, Merlo A, et al. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette- Guerin: Five-year results of a prospective randomized study. Cancer 1996;77:2560-6
122. Repmann R, Wagner S, Richter A. Adjuvant therapy of renal cell carcinoma with active-specific-immunotherapy (ASI) using autologous tumor vaccine. Anticancer Res 1997;17:2879-82
123. Jocham D, Richter A, Hoffmann L, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial. Lancet 2004;363:594-9
124. Wood C, Srivastava P, Bukowski R, et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: A multicentre, open-label, randomised phase III trial. Lancet 2008;372:145-54
125. Walter S, Weinschenk T, Stenzl A, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012; Epub ahead of print
126. IMA901 in patients receiving sunitinib for advanced/metastatic renal cell carcinoma. Available from: Http:/ clinicaltrials.gov/ct2/show/NCT01265901